LAUSR

4 We developed a cell therapy product, DUOC-01, derived from banked human umbilical cord blood, to treat demyelinating conditions in the central nervous system. Previously, we demonstrated that DUOC-01 increased myelination and decreased gliosis and cellular infiltration in the corpus callosum of immune-incompetent mice treated with cuprizone. To investigate the mechanism and test whether DUOC-01 will be efficacious in other models of demyelination, we tested DUOC-01 in lysophosphatidylcholine (LPC) demyelinated murine organotypic cerebellar brain slices and a mouse model of experimental autoimmune encephalomyelitis (EAE). In the cerebellar brain slice culture model, we found that DUOC-01 treatment enhanced remyelination of LPC-mediated demyelinated neurons compared with the untreated control samples. These data demonstrate that DUOC-01 is capable of accelerating the remyelination of neurons by reducing gliosis and promoting oligodendrocyte proliferation and promoting myelin debris clearance. Currently, we are testing the ability of DUOC-01 to limit inflammation in EAE. Also, we are analyzing single cell sequencing data to determine various populations present in DUOC-01 cultures and to understand the functional pathways responsible for promoting remyelination. Overall, our data suggest that DUOC-01 could be beneficial in treating demyelinating conditions. STEM CELLS TRANSLATIONAL MEDICINE | StemCellsTM.com © AlphaMed Press 2018 PRECLINICAL STUDIES Official journal of the